Health24.com | WATCH: Women may sleep better with a dog

Sleep disorders expert

Dr Alison Bentley is a general practitioner who has consulted in sleep medicine and sleep disorders, in both adults and children of all ages, for almost 30 years. She also researches and publishes on a number of sleep-related topics both in formal research journals and lay publications including as editor of Sleep Matters, an educational newsletter on sleep disorders for doctors.

Share Button

Free NHS hospital parking for thousands in ‘greatest need’

People with disabilities and NHS staff on night shifts will be among those to benefit from April.

Share Button

Injection of virus-delivered gene silencer blocks ALS degeneration, saves motor function

Writing in Nature Medicine, an international team headed by researchers at University of California San Diego School of Medicine describe a new way to effectively deliver a gene-silencing vector to adult amyotrophic lateral sclerosis (ALS) mice, resulting in long-term suppression of the degenerative motor neuron disorder if treatment vector is delivered prior to disease onset, and blockage of disease progression in adult animals if treatment is initiated when symptoms have already appeared.

The findings are published in the December 23, 2019 online issue of the journal Nature Medicine. Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine and a member of the Sanford Consortium for Regenerative Medicine, is senior author of the study.

ALS is a neurodegenerative disease that affects nerve cells in the brain and spinal cord. Motor neurons responsible for communicating movement are specifically harmed, with subsequent, progressive loss of muscle control affecting the ability to speak, eat, move and breathe. More than 5,000 Americans are diagnosed with ALS each year, with an estimated 30,000 persons currently living with the disease. While there are symptomatic treatments for ALS, there is currently no cure. The majority of patients succumb to the disease two to five years after diagnosis.

There are two types of ALS, sporadic and familial. Sporadic is the most common form, accounting for 90 to 95 percent of all cases. It may affect anyone. Familial ALS accounts for 5 to 10 percent of all cases in the United States, and is inherited. Previous studies show that at least 200 mutations of a gene called SOD1 are linked to ALS.

The SOD1 gene normally serves to provide instructions for making an enzyme called superoxide dismutase, which is widely used to break down superoxide radicals — toxic oxygen molecules produced as a byproduct of normal cell processes. Previous research has suggested that SOD1 gene mutations may result in ineffective removal of superoxide radicals or create other toxicities that cause motor neuron cell death, resulting in ALS.

The new approach involves injecting shRNA — an artificial RNA molecule capable of silencing or turning off a targeted gene — that is delivered to cells via a harmless adeno-associated virus. In the new research, single injections of the shRNA-carrying virus were placed at two sites in the spinal cord of adult mice expressing an ALS-causing mutation of the SOD1 gene, either just before disease onset or when the animals had begun showing symptoms.

Earlier efforts elsewhere had involved introducing the silencing vector intravenously or into cerebrospinal fluid in early symptomatic mice, but disease progression, while delayed, continued and the mice soon died. In the new study, the single subpial injection (delivered below the pia matter, the delicate innermost membrane enveloping the brain and spinal cord) markedly mitigated neurodegeneration in pre-symptomatic mice, which displayed normal neurological function with no detectable disease onset. The functional effect corresponded with near-complete protection of motor neurons and other cells, including the junctions between neurons and muscle fibers.

In adult mice already displaying ALS-like symptoms, the injection effectively blocked further disease progression and degeneration of motor neurons.

In both approaches, the affected mice lived without negative side effects for the length of the study.

“At present, this therapeutic approach provides the most potent therapy ever demonstrated in mouse models of mutated SOD1 gene-linked ALS,” said senior author Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine.

“In addition, effective spinal cord delivery of AAV9 vector in adult animals suggests that the use of this new delivery method will likely be effective in treatment of other hereditary forms of ALS or other spinal neurodegenerative disorders that require spinal parenchymal delivery of therapeutic gene(s) or mutated-gene silencing machinery, such as in C9orf72 gene mutation-linked ALS or in some forms of lysosomal storage disease.”

The research team also tested the injection approach in adult pigs, whose spinal cord dimensions are similar to humans, for safety and efficacy. Using an injection device developed for use in adult humans, they found the procedure could be performed reliably and without surgical complications.

Marsala said next steps involve additional safety studies with a large animal model to determine the optimal, safe dosage of treatment vector. “While no detectable side effects related to treatment were seen in mice more than one year after treatment, the definition of safety in large animal species more similar to humans is a critical step in advancing this treatment approach toward clinical testing.”

Share Button

Researchers map malaria parasites proliferating in human blood cells

Malaria parasites transform healthy red blood cells into rigid versions of themselves that clump together, hindering the transportation of oxygen. The infectious disease affects more than 200 million people across the world and causes nearly half a million deaths every year, according to the World Health Organization’s 2018 report on malaria. Until now, however, researchers did not have a strong understanding of how the parasite so effectively infiltrated a system’s red blood cells.

Now, researchers have detailed a comprehensive interaction network map of how malaria traffics between human host cells. They published their results on Sept. 27 in iScience, a Cell Press journal.

The researchers focused on Plasmodium falciparum, the parasite that causes the most severe form of malaria. This parasite infects a host red blood cell, triggering the production of several proteins into the host cell’s cytoplasm — the bulk of the cell’s mechanics and the liquid in which they’re held, ultimately transforming the cell’s physical form. Not only does this transformation make the cells stick in place, out of the body’s immune response, it also helps the parasite travel to the surface of the cell and infect others. Together, the proteins work to proliferate the parasite, leading to the propagation of the malaria parasite.

“Our study sheds light on the highly complicated interplay between parasite and host proteins in the host cytoplasm,” said Kentaro Kato, professor in the Laboratory of Sustainable Animal Environment in Tohoku University Graduate School of Agricultural Science and paper authors. “The work provides a reliable dataset of the interactions connecting dozens of proteins the parasite exports to continue infecting the host cells.”

Previously, it was difficult to understand how the parasite works with the triggered proteins because the parasite was predicted to export about 400 proteins, yet another study found that proteins without the specific genetic sequence could also be exported to the cell’s cytoplasm. In this study, the researchers opted to focus on one of these proteins without the parasitic mark — skeleton-binding protein 1 (SBP1), which is known to be highly important for malaria to propagate. By studying a protein known to be related to malaria virulence, but that isn’t specifically triggered by the parasitic proteins, the researchers could narrow in on specific protein interactions to understand how the infection traffics within and beyond the host cells.

They used highly sensitive mass spectrometry to image the proteins interacting with SBP1 throughout the proliferation process, leading to the identification of several proteins specifically connected to transforming the host cell.

“In this study, we developed an alternative approach to identify exported proteins involved in the trafficking complex and in the parasite protein exports,” Kato said. “The SBP1 interactions established in our study represent a powerful and invaluable platform to identify exported proteins related to severe malaria caused by Plasmodium falciparum.”

The research provided a comprehensive map of SBP1 interactions which shed light on the complex relationships and interplay between host and parasite proteins. The findings also pave the way for further study and discussion on the molecular mechanism of the infections that affect human red blood cells.

Story Source:

Materials provided by Tohoku University. Note: Content may be edited for style and length.

Share Button

Contaminated blood scandal: Welsh frustration at payments wait

Victims of the contaminated blood scandal worry they may die before payment parity issues are resolved.

Share Button

Baby video messages ‘amazing’ for new parents

Victoria’s triplets spent nine weeks in Southampton’s neonatal unit and staff sent updates via a new app.

Share Button

Brain tumor organoids may be key to time-sensitive treatments for glioblastomas

Lab-grown brain organoids developed from a patient’s own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.

Glioblastoma multiforme (GBM) remains the most difficult of all brain cancers to study and treat, largely because of tumor heterogeneity. Treatment approaches, like surgery, radiation and chemotherapy, along with newer personalized cellular therapies, have proven to slow tumor growth and keep patients disease-free for some periods of time; however, a cure remains elusive.

“While we’ve made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective treatments,” said senior author Hongjun Song, PhD, Perelman Professor of Neuroscience in the Perelman School of Medicine at the University of Pennsylvania. “One hurdle is the ability to recapitulate the tumor to not only better understand its complex characteristics, but also to determine what therapies post-surgery can fight it in a timelier manner.”

Co-senior authors include Guo-li Ming, MD, PhD, Perelman Professor of Neuroscience, and Donald O’Rourke, MD, the John Templeton, Jr., MD Professor in Neurosurgery, and director of the GBM Translational Center of Excellence at Penn’s Abramson Cancer Center.

Lab-grown brain organoids — derived from human pluripotent stem cells or patient tissues and grown to a size no bigger than a pea — can recapitulate important genetic composition, brain cell type heterogeneity, and architecture, for example. These models are allowing researchers to recreate key features of patients’ diseased brains to help paint a clearer picture of their cancer, and allowing them to explore ways to best attack it.

What makes organoids so attractive in GBM is timing and the ability to maintain cell type and genetic heterogeneity. While existing in vitro models have added to researchers’ understanding of the biological mechanisms underlying the cancer, they have limitations. Unlike other models, which need more time to exhibit gene expression and other histological features that more closely represent the tumor, brain tumor organoids developed by the research group grow into use much more rapidly. That’s important because current treatment regimens are typically initiated one month following surgery, so having a road map sooner is more advantageous.

In the new study, the researchers removed fresh tumor specimens from 52 patients to “grow” corresponding tumor organoids in the lab. The overall success rate for generating glioblastoma organoids (GBOs) was 91.4 percent, with 66.7 percent of tumors expressing the IDH1 mutation, and 75 percent for recurrent tumors, within two weeks. These tumor glioblastoma organoids can also be biobanked and recovered later for analyses.

Genetic, histological, molecular analyses were also performed in 12 patients to establish that these new GBOs had largely retained features from the primary tumor in the patient.

Eight GBO samples were then successfully transplanted into adult mouse brains, which displayed rapid and aggressive infiltration of cancer cells and maintained key mutation expression up to three months later. Importantly, a major hallmark of GBM — the infiltration of tumor cells into the surrounding brain tissue — was observed in the mouse models.

To mimic post-surgery treatments, the researchers subjected GBOs to standard-of-care and targeted therapies, including drugs from clinical trials and chimeric antigen receptor T (CAR-T) cell immunotherapy. For each treatment, researchers showed that the organoid responses are different and effectiveness is correlated to their genetic mutations in patient tumors. This model opens the possibility for future clinical trials for personized treatment based on individual patient tumor responses to various different drugs.

Notably, the researchers observed a benefit in the organoids treated with CAR T therapies, which have been used in ongoing clinical trials to target the EGFRvIII mutation, a driver of the disease. In six GBOs, the researchers showed specific effect to patient GBOs with the EGFRvIII mutation with an expansion of CAR T cells and reduction in EGFRvIII expressing cells.

“These results highlight the potential for testing and treating glioblastomas with a personalized approach. The ultimate goal is to work towards a future where we can study a patient’s organoid and test which CAR T cell is going to be the best against their tumor, in real time.” O’Rourke said. “A shorter-term goal, given the heterogeneity of glioblastomas, is that in vitro testing of various therapeutic options may also help refine patient enrollment in clinical trials, by more accurately defining mutations and selecting the appropriate, available targeted therapies for each.”

Share Button

In vivo imaging of CREB dynamics: Coupling sensory experience to activity

Our brains have a remarkable knack for adaptability. Each and every day the neuronal connections within are constantly changing, molded by what we experience in our daily lives. The memories we make, information learned and skills we pick up spark this dynamic process, causing lasting changes to neuronal circuits. As the saying goes, experience is the best teacher and it couldn’t be truer for our brains.

Along with learning and memory, sensory experiences such as listening to music or appreciating a stunning view also have a similar effect on the brain. Incoming sensory information activates neurons in the cortex, causing long term modifications to the circuitry depending on what we experience. This process called experience dependent plasticity, is part of the reason why our brains develop differently due to unique individual life experiences.

But how do our brains convert relatively short-lasting neuronal activity into the long-term changes driven by our sensory experiences? The key lies in specialized proteins called activity-dependent transcription factors. Responding to neuronal activity, these factors activate genes within the cell helping to translate rapid incoming signaling into slower, lasting changes. Despite the importance of activity dependent transcription to development and long-term plasticity in the brain is evident, it was impossible to directly monitor transcription factors activity. This was mainly due to the lack of available tools to study the interaction between neuronal activity and transcription factor activation that occurs in an intact, living brain.

In a recently published study in Neuron, Scientists in the Yasuda Lab at the Max Planck Florida Institute for Neuroscience (MPFI) have designed and developed novel biosensors that allow the simultaneous study of both sensory evoked neuronal activity and transcription factor dynamics. Coupling the specialized techniques of 2-photon calcium imaging with 2-photon fluorescence lifetime imaging (2pFLIM), scientists for the first time ever will have the unique ability to investigate how transcription factors function in a living brain with single cell resolution.

“Transcription factor activity in the brain isn’t a static, but rather a very dynamic process that can occur on the order of hours to days after a sensory experience,” explains Dr. Tal Laviv, Research Fellow in the Yasuda Lab and leading author of the paper. “Traditional methods of studying these proteins involve freezing brain tissue at a single moment in time. So, while these approaches can tell you if a certain factor is activated or not, they aren’t good at capturing how experience shapes transcription factor activity over time. We wanted to develop a new way to study how this process is actually occurring in a living brain and chose to study CREB due to its strong involvement in plasticity, learning and memory.”

MPFI scientists started by creating sensitive and specific 2pFLIM biosensors designed to report the direct activity of cAMP response-element binding protein or “CREB” for short. Packaging their newly generated sensors using an adeno-associated viral strategy (AAVs), the team then expressed them in a population of neurons within the somatosensory cortex of mice. Changes in environment are known to activate this brain region and in response, the neurons within modulate numerous signaling molecules including CREB. But little is known about the temporal dynamics of CREB activation after a change to the environment. Using the 2pFLIM CREB sensor, the team chronically monitored CREB activity in the same population of neurons while mice experienced an enriched environment. The enriched environment caused a significant increase in overall CREB activity. Interestingly, when mice were removed from the enriched environment for an extended period of time, CREB activity returned to normal levels indicating sensory experience as a driver for the sustained activity.

Next, MPFI scientists sought to unravel how sensory experiences and neuronal activation shape CREB activity in the living brain. To do so, the team expressed the CREB sensor and a sensor of neuronal activity (calcium sensor) in the visual cortex of mice. Previous studies have shown that when mice are temporarily deprived of visual stimuli and placed in dark housing, neuronal plasticity was increased in the visual cortex. In the new study, visual cortical neurons were imaged in dark-reared mice during presentation of a visual stimuli. Both calcium and CREB dynamics in single cells were simultaneously imaged for prolonged periods of time. The results revealed a dynamic regulation of CREB activity in the visual cortex: Dark reared mice displayed dramatically increased levels of visually evoked CREB compared to mice raised in normal light/dark conditions. In addition, CREB activity levels were maintained for a period of at least one day in dark-reared mice. Intriguingly this elevated CREB activity was not due to elevated calcium levels within individual neurons, indicating that sensory experience can finely tune the sensitivity of activity dependent transcription in the living brain.

This unique approach can be broadly applied to many different types of transcription factors in the future and will allow an unprecedented opportunity to unravel the transcriptional dynamics underlying experience-dependent plasticity in the brain.

Story Source:

Materials provided by Max Planck Florida Institute for Neuroscience. Note: Content may be edited for style and length.

Share Button

Finally, machine learning interprets gene regulation clearly

In this age of “big data,” artificial intelligence (AI) has become a valuable ally for scientists. Machine learning algorithms, for instance, are helping biologists make sense of the dizzying number of molecular signals that control how genes function. But as new algorithms are developed to analyze even more data, they also become more complex and more difficult to interpret. Quantitative biologists Justin B. Kinney and Ammar Tareen have a strategy to design advanced machine learning algorithms that are easier for biologists to understand.

The algorithms are a type of artificial neural network (ANN). Inspired by the way neurons connect and branch in the brain, ANNs are the computational foundations for advanced machine learning. And despite their name, ANNs are not exclusively used to study brains.

Biologists, like Tareen and Kinney, use ANNs to analyze data from an experimental method called a “massively parallel reporter assay” (MPRA) which investigates DNA. Using this data, quantitative biologists can make ANNs that predict which molecules control specific genes in a process called gene regulation.

Cells don’t need all proteins all the time. Instead, they rely on complex molecular mechanisms to turn the genes that produce proteins on or off, as needed. When those regulations fail, disorder and disease usually follow.

“That mechanistic knowledge — understanding how something like gene regulation works — is very often the difference between being able to develop molecular therapies against diseases, and not being able to,” Kinney said.

Unfortunately the way standard ANNs are shaped from MPRA data is very different from how scientists ask questions in the life sciences. This misalignment means that biologists find it difficult to interpret how gene regulation occurs.

Now, Kinney and Tareen developed a new approach that bridges the gap between computational tools and how biologists think. They created custom ANNs that mathematically reflect common concepts in biology concerning genes and the molecules that control them. In this way, the pair are essentially forcing their machine learning algorithms to process data in a way that a biologist can understand.

These efforts, Kinney explained, highlight how modern, industrial AI technologies can be optimized for use in the life sciences. Having verified this new strategy to make custom ANNs, Kinney’s lab is applying it in investigating a wide variety of biological systems, including key gene circuits involved in human disease.

Story Source:

Materials provided by Cold Spring Harbor Laboratory. Original written by Brian Stallard. Note: Content may be edited for style and length.

Share Button

Health24.com | WATCH: Top foods that can make your skin glow

26 December 2019

WATCH: Top foods that can make your skin glow

No need to fork out hundreds of rands to get that glow – here’s how you can achieve it the natural way.

Stringr

These nutrients are common in skincare products, but why not let your skin benefit from them in your diet too?

Image: Getty

NEXT ON HEALTH24X

Live healthier

Share Button